Jane Street Group, LLC Sage Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$444 Billion
Q4 2024

A detailed history of Jane Street Group, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 462,004 shares of SAGE stock, worth $3.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

462,004

Previous 227,476 103.1%

Holding current value

$3.38 Million

Previous $1.64 Million 52.93%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.78 - $8.57 $1.12 Million - $2.01 Million	234,528 Added 103.1%	462,004 $2.51 Million
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $144,253 - $268,780	-20,549 Reduced 8.29%	227,476 $1.64 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $460,653 - $779,365	43,540 Added 21.29%	248,025 $2.69 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $2.52 Million - $3.65 Million	135,497 Added 196.41%	204,485 $3.83 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $1.53 Million - $1.99 Million	-89,231 Reduced 56.4%	68,988 $1.49 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $969,104 - $2.83 Million	57,857 Added 57.65%	158,219 $3.26 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $2.49 Million - $3.65 Million	61,240 Added 156.54%	100,362 $4.72 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $1.88 Million - $2.35 Million	-50,480 Reduced 56.34%	39,122 $1.64 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $2.89 Million - $3.91 Million	89,602 New	89,602 $3.42 Million
Q2 2022 Aug 16, 2022	SELL	$27.52 - $37.99 $2.85 Million - $3.94 Million	-103,587 Reduced 63.86%	58,625 $1.89 Million
Q1 2022 May 17, 2022	BUY	$30.71 - $45.71 $2.47 Million - $3.67 Million	80,384 Added 98.24%	162,212 $5.37 Million
Q4 2021 Feb 15, 2022	BUY	$37.06 - $47.11 $794,825 - $1.01 Million	21,447 Added 35.52%	81,828 $3.48 Million
Q3 2021 Nov 16, 2021	BUY	$40.26 - $57.37 $1.82 Million - $2.59 Million	45,113 Added 295.47%	60,381 $2.68 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $2.52 Million - $3.64 Million	-45,962 Reduced 75.06%	15,268 $867,000
Q1 2021 May 18, 2021	SELL	$70.65 - $96.76 $1.49 Million - $2.04 Million	-21,125 Reduced 25.65%	61,230 $4.58 Million
Q4 2020 Feb 17, 2021	BUY	$58.41 - $89.06 $3.18 Million - $4.86 Million	54,517 Added 195.84%	82,355 $7.13 Million
Q3 2020 Nov 17, 2020	SELL	$41.13 - $62.45 $287,498 - $436,525	-6,990 Reduced 20.07%	27,838 $1.7 Million
Q2 2020 Aug 17, 2020	SELL	$25.95 - $43.15 $377,728 - $628,091	-14,556 Reduced 29.48%	34,828 $1.45 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $2.48 Million - $6.37 Million	41,164 Added 500.78%	49,384 $3.57 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $802,178 - $1.09 Million	5,718 Added 228.54%	8,220 $1.15 Million
Q2 2019 Aug 15, 2019	SELL	$157.85 - $183.09 $1.95 Million - $2.27 Million	-12,381 Reduced 83.19%	2,502 $458,000
Q1 2019 May 16, 2019	BUY	$89.33 - $163.65 $873,379 - $1.6 Million	9,777 Added 191.48%	14,883 $2.37 Million
Q4 2018 Feb 15, 2019	BUY	$81.94 - $139.71 $418,385 - $713,359	5,106 New	5,106 $489,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $5.74 Million - $7.02 Million	-41,549 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$140.36 - $175.76 $5.46 Million - $6.84 Million	38,931 Added 1487.05%	41,549 $6.5 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $1.86 Million - $2.36 Million	-12,254 Reduced 82.4%	2,618 $422,000
Q4 2017 Feb 15, 2018	BUY	$60.72 - $167.34 $106,502 - $293,514	1,754 Added 13.37%	14,872 $2.45 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $805,445 - $1.16 Million	13,118	13,118 $817,000

Others Institutions Holding SAGE

# of Institutions

194

Shares Held

45M

Call Options Held

304K

Put Options Held

117K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $434M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Sage Therapeutics, Inc. Transaction History